Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
Krane
Vera
V
Wanner
Christoph
C
D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D002908:Chronic Disease; D018450:Disease Progression; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000097:blood / Q000150:complications* / Q000601:surgery / Q000628:therapy; D016030:Kidney Transplantation / Q000706:statistics & numerical data; D010530:Peritoneal Dialysis / Q000706:statistics & numerical data; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000706:statistics & numerical data; D012107:Research Design; D019821:Simvastatin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D002784:Cholesterol; D019821:Simvastatin; D001241:Aspirin